VIMOVO delivers what naproxen 500 mg alone cannot—less risk of developing stomach ulcers
Naproxen relieves signs and symptoms of:
- Osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS) in adults
- Juvenile idiopathic arthritis (JIA) in adolescents*
- Esomeprazole Magnesium decreases the risk of developing stomach ulcers from naproxen
VIMOVO delivers relief from OA/RA pain and inflammation with at least 70% lower risk of developing stomach ulcers than patients on naproxen alone
If you have osteoarthritis or rheumatoid arthritis, chronic NSAID use can put you at risk
- 1 in 4 people taking NSAIDs regularly, like naproxen, may develop a stomach ulcer
- Stomach ulcers can occur in under 1 week
- Most people will never even feel the stomach ulcer developing—but stomach ulcers can be very dangerous and lead to serious health complications
A medicine that reduces the risk to your stomach is called gastroprotective
- Experts recommend taking a gastroprotective medicine with NSAIDs, as one way to decrease the possibility of getting stomach ulcers in certain patients
Ask your doctor if VIMOVO may be right for you—only VIMOVO gives you Naproxen and Esomeprazole at the same time in 1 tablet
- Only VIMOVO provides relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis AND built-in gastroprotective medicine to reduce the risk of developing stomach ulcers with every dose of naproxen in a single tablet
The most common side effects of VIMOVO are inflammation of the lining of the stomach and diarrhea
Experts agree that certain patients on NSAIDs should also take gastroprotective medicine
*VIMOVO is indicated for relief of signs and symptoms of juvenile idiopathic arthritis (JIA) in adolescent patients 12 years of age and older weighing at least 84 pounds (38 kg)
- Advil [drug facts]. Madison, NJ; Pfizer Consumer Healthcare; 2014.
- Aleve [drug facts]. Whippany, NJ:Bayer Healthcare Consumer Care; 2014.
- Ibuprofen overview. https://www.drugs.com/ibuprofen.html. Accessed September 19, 2016.
- MOBIC(meloxicam) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. May 2016.
- Naproxen [drug facts]. Nutley, NJ: RocheLaboratories Inc; 2004.
- Lanza FL, Chan FKL, Quigley EMM. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728-738
- Desai JC, Sanyal SM, Goo T, et al. Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatorydrugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study. Dig Dis Sci. 2008;53(8):2059-2065.
- Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa anddyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 1987;82(11):1153-1158.
- Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-474.
- Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am Fam Physician. 2009;80(12):1371-1378.
- Sturkenboom MC, Burke TA, Tangelder MJD, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003;18:1137-1147.